Christopher Wright
Director/Board Member presso ALKERMES PLC
Patrimonio netto: 196 772 $ in data 31/03/2024
Profilo
Christopher I.
Wright is an Independent Director at Alkermes Plc and the Chief Medical Officer at Ring Therapeutics, Inc. He previously held positions as the SVP-Global Medicines Development & Medical Affairs at Vertex Pharmaceuticals, Inc., the Chief Development Officer & SVP-Global Development at Ironwood Pharmaceuticals, Inc., an Associate Professor at Harvard Medical School, the Chief Medical Officer & Senior Vice President at Axcella Health, Inc., the Chief Medical Officer & Senior Vice President at Cyclerion Therapeutics, Inc., and the Chief Medical Officer at Aavantibio, Inc. Dr. Wright received his undergraduate degree from Harvard University and his doctorate from Vrije Universiteit Amsterdam.
He also holds graduate and doctorate degrees from Harvard Medical School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 07/07/2023 | 7 269 ( 0.00% ) | 196 772 $ | 31/03/2024 |
Posizioni attive di Christopher Wright
| Società | Posizione | Inizio |
|---|---|---|
| ALKERMES PLC | Director/Board Member | 24/05/2022 |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Precedenti posizioni note di Christopher Wright
| Società | Posizione | Fine |
|---|---|---|
| CYCLERION THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 26/03/2021 |
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Chief Tech/Sci/R&D Officer | - |
| Harvard Medical School | Corporate Officer/Principal | - |
| IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| AXCA HEALPAR | Chief Tech/Sci/R&D Officer | - |
Formazione di Christopher Wright
| Harvard University | Undergraduate Degree |
| Vrije Universiteit Amsterdam | Doctorate Degree |
| Harvard Medical School | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| AXCA HEALPAR | Health Technology |
| CYCLERION THERAPEUTICS, INC. | Health Technology |
| ALKERMES PLC | Health Technology |
| Aziende private | 2 |
|---|---|
Ring Therapeutics, Inc.
Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Health Technology |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Health Technology |
- Borsa valori
- Insiders
- Christopher Wright
